All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche, and Syndax, and supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How can outcomes be improved in patients with molecularly-defined high-risk AML?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Alice Mims, Ohio State University Comprehensive Cancer Center - The James, Columbus, US. We asked, How can outcomes be improved in patients with molecularly-defined high-risk acute myeloid leukemia (AML)?
How can outcomes be improved in patients with molecularly-defined high-risk AML?
Mims outlines the use of the 2022 European LeukemiaNet risk classification in molecularly defining high-risk AML and discusses the importance of cytogenetics and sequencing at the time of diagnosis to guide treatment decisions and determine eligibility for clinical trials. Mims goes on to discuss data presented at ASH on patients with TP53 mutations, FLT3-ITD, and KMT2A rearrangements treated with therapeutics including azacitidine, venetoclax, magrolimab, eprenetapopt (APR-246), gilteritinib, and revumenib (SNDX-5613).
Your opinion matters
10 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox